Non-Invasive Cancer Diagnostics Market Outlook

Valued at USD 78.77 billion in 2025, the non-invasive cancer diagnostics market is projected to reach USD 83.92 billion in 2026 and USD 143.60 billion by 2034, growing at a CAGR of 6.9% during the forecast period 2026–2034. Key players include Bio-Rad Laboratories, Inc.; Danaher Corporation; Exact Sciences Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; Guardant Health; Illumina; Koninklijke Philips N.V.; QIAGEN N.V.; Siemens Healthineers AG; Sysmex Corporation; and Thermo Fisher Scientific Inc. The report segments the market by technology, cancer type, and end user.

Lung Cancer Leads by Cancer Type

By cancer type, lung cancer held a 30.5% share in 2025, the largest in the segment. The report cites WHO data showing that lung cancer accounted for 2.5 million cases and 1.8 million deaths worldwide in 2022. The scale of this burden underlines the importance of diagnostic approaches that can identify disease without invasive procedures.

Colorectal Cancer Shows the Fastest Growth

Colorectal cancer is the fastest-growing cancer type, with a CAGR of 7.4% during 2026–2034, ahead of the overall market growth rate of 6.9%. Breast, prostate, and other cancers are also covered by the segmentation, although the report does not publish figures for them. Suppliers focused on screening and monitoring tests may find opportunity in the faster growth of colorectal applications.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/non-invasive-cancer-diagnostics-market

Prostate Cancer Innovation

In April 2026, PanGIA Biotech revealed a urine-based AI liquid biopsy for prostate cancer, reporting 97.8% sensitivity. The development shows how non-invasive sample types are being applied to specific cancers. Other recent activity includes the February 2026 FDA Breakthrough Device designation for ErlySign's saliva-based oral cancer test and Darwin AG's March 2026 commercialization of its Multi-Cancer Check blood test, which covers 13 cancer types.

Hospitals Dominate End-User Demand

By end user, hospitals held a 44.56% share in 2025, the largest in the segment. Their lead makes hospitals the primary reference point for suppliers of non-invasive testing platforms. Cancer research centers and specialty clinics are also covered by the segmentation, with no figures provided.

Diagnostic Laboratories Are the Fastest-Growing End User

Diagnostic laboratories are the fastest-growing end user, although the report does not provide a CAGR value. Suppliers that serve laboratory customers with reliable platforms and consumables are positioned to benefit from this pace, which is faster than the overall market is expected to grow.

Early Detection as the Primary Driver

Demand for early detection is the main driver identified in the report. Non-invasive methods can lower barriers to screening because they avoid tissue sampling. The report also notes reimbursement and regulatory barriers as challenges, which can delay market entry and adoption despite clinical interest.

Regional Growth Patterns

North America was the largest region in 2025, with a 40.79% share, led by the U.S. Europe held a 28% share. Asia Pacific is the fastest-growing region, with a CAGR of 7.5%. The report cites Cancer Atlas data showing that Southern, Eastern, and Southeast Asia account for about 9.2 million new cases and 5.1 million deaths annually, indicating the scale of need in the region.

Funding and Innovation Signals

In October 2025, OraLiva raised USD 2 million in seed funding for an AI platform for non-invasive cancer diagnosis through cytology. Early-stage investment of this kind indicates continued interest in new approaches to detection.

Competitive Landscape and Strategic Outlook

The report names 12 key players, including Bio-Rad Laboratories, Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Foundation Medicine, Guardant Health, Illumina, Koninklijke Philips N.V., QIAGEN N.V., Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific. With a 6.9% CAGR through 2034, suppliers that serve hospitals and laboratories across major cancer types are well positioned for growth.

More Trending Latest Reports By Polaris Market Research:

digital-detox-tourism-services-market

biodegradable-packaging-market

aircraft-manufacturing-market

global-chocolate-market

precision-farming-market

protein-alternatives-market

patient-engagement-solutions-market

5g-fixed-wireless-access-market

automotive-telematics-market